Healthy Volunteer Clinical Trial
— BRAINDYNOfficial title:
Tracking Information Flow in the Brain: A Unified and General Framework for Dynamic Communication in Brain Networks
The brain is composed of a set of areas specialized in specific computations whose outputs need to be transferred to other specialized areas for cognition to emerge. To account for context-dependent behaviors, the information must be flexibly routed through the fixed anatomy of the brain. The aim of this project is to test a general framework for this flexible communication between brain areas based on nested oscillations. The general idea is that internally-driven slow oscillations (<20Hertz) either set-up or prevent the communication between brain areas. Stimulus-driven gamma oscillations (>30Hertz), nested in the slow oscillations, can then be directed to task-relevant areas of the network. This multimodal, multi-scale approach uses magnetoencephalography using a 3-Dimensional (3D) printed individual head-cast system and transcranial stimulation in experiments manipulating visual processing, attention and memory to test core predictions of this framework. The theoretical approach and the methodological development used in this basic science study will provide the basis for future fundamental and clinical research.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | October 25, 2027 |
Est. primary completion date | October 25, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 36 Years |
Eligibility | Inclusion Criteria: - 20-36 years old - Right handed - Registered with the French healthcare system - Motivated to participate in the study - Normal or corrected vision - Adequate knowledge of French to be able to follow directions and give informed consent - Capacity to listen and follow study instructions - Use of contraception (in sexually active women) - BMI between 18.5 and 30 - Informed consent for participation in the study Exclusion Criteria: - For All Experiments: - Persons with : - Sleep disorders, neurological or psychiatric illnesses or a history of such problems that could impact quality/variability of data or cooperation and retention of the subject in the study - Migraines or light-sensitive epilepsy - Regular use of medications that impact the central nervous system - Regular use of medications, such as opioids and antidepressants, including Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants - Severe hearing loss - Skin conditions or allergies - Chronic pain, or any other medical conditions conducive to pain sensitivity - A history of stroke or recent trauma to the head - A pacemaker, insulin or other pump, neurostimulator, cochlear implants or other hearing aid, metal stents, prosthesis, or implants, intracerebral clips, implantable defibrillator, cerebral shunt or ventricular catheter, other foreign metal objects in the upper part of the body - Persons unable to adhere to abstinence from the use of drugs or alcohol the day or evening before experimental sessions - Women who are pregnant, breastfeeding, or have given birth in the last 6 months For experiments using magnetoencephalography: - Persons with - claustrophobia - any dental apparatus containing metal including or root canals - any foreign metallic object anywhere in the body - bolts, screws - orthopedic devices or implants - glasses (given the participant cannot use contact lenses) - a head size incompatible with the use of a personalized 3D head-cast or a magnetoencephalograph - Persons having had any surgery prior to the study which puts them at risk for metal objects left in the body For experiments using Magnetic Resonance Imaging (MRI) or Functional Magnetic Resonance Imaging (fMRI) techniques: - Anxious, non-cooperative, or agitated persons - Claustrophobia - Persons having had any surgery prior to the study which puts them at risk for metal objects left in the body For experiments using transcranial stimulation: -Persons with frequent syncope episodes (loss of consciousness) as a result of any particular sensorial stimulations |
Country | Name | City | State |
---|---|---|---|
France | Centre de Recherche en Neuroscience de Lyon INSERM | Bron |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The composite characteristics of the brain oscillations (frequency, synchronization, and interaction between brain oscillations in and between different brain regions and networks) | The primary outcome measure is measured using fMRI bold signals (experiment 1), and brain signals obtained through electroencephalography (experiment 1, 3) and magnetoenecephalography (experiment 1, 3), depending on the sessions. The signals are then transformed during analyses and patterns in the composite characteristics are identified. | up to 17 months | |
Secondary | The coupling of behavioral responses to stimuli with physiological responses in the brain. | Throughout the sessions of neuroimaging. There are 5, 1 or 2, and 1 sessions of neuroimaging for experiment 1, 2, and 3 respectively. The 5 sessions of experiment 1 are over a period of 1 to 17 months. Each session lasts approximately 3 hours including setup.The sessions take place at between 7 and 198 days after inclusion. The time between the sessions is variable. | up to 17 months | |
Secondary | Coupling of brain oscillation characteristics in responses to the "flickering" effect | There are 5 sessions of neuroimaging for experiment 1. The 5 sessions of experiment 1 are over a period of 1 to 17 months. Each session lasts approximately hours including setup. This outcome measure will be recorded during these 5 interspaced sessions, at between 7 and 198 days after inclusion. The time between the sessions is variable. | up to 17 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01433575 -
A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers
|
Phase 1 | |
Completed |
NCT01461967 -
A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01414881 -
Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
|
Phase 1 |